Rare Cancer News & Clinical Trials » Trial

Trial - Adrenocortical Carcinoma (43 unread)

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Posted: November 21st, 2023, 3:00am GMT

Conditions: Adrenal Cortical Carcinoma; Medullary Thyroid Cancer; Thymic Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Tumor
Interventions: Biological: individualized mRNA neoantigen vaccine (mRNA-0523-L001)
Sponsors: Shanghai Jiao Tong University School of Medicine
Not yet recruiting
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC

Posted: November 9th, 2023, 3:00am GMT

Conditions: Extensive Small Cell Lung Cancer
Interventions: Drug: Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy
Sponsors: Qianfoshan Hospital
Recruiting
Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer

Posted: October 5th, 2023, 2:00am GMT

Conditions: Thyroid Cancer, Papillary; Primary Aldosteronism
Interventions: Diagnostic Test: Secreening test for primary aldosteronism and Confirmatory Testing
Sponsors: Instituto do Cancer do Estado de São Paulo; Fundação de Amparo à Pesquisa do Estado de São Paulo
Completed
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Posted: October 4th, 2023, 2:00am GMT

Conditions: Adrenocortical Carcinoma; ACC; Metastatic Adrenocortical Carcinoma
Interventions: Radiation: Ablative Radiotherapy; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center
Recruiting
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy

Posted: September 22nd, 2023, 2:00pm GMT

Conditions: Adrenal Tumor; Adrenal Disease; Adrenal Mass; Adrenalectomy; Status; Adrenal Hyperplasia; Adrenal Gland Metastasis; Adrenal Cortex Diseases; Pheochromocytoma; Cushing Syndrome; Conn Adenoma; Adrenocortical Carcinoma; Adrenocortical Adenoma; Adrenocortical Tumor
Sponsors: University Hospital Olomouc; University Hospital Ostrava; Tomas Bata Hospital, Czech Republic; General University Hospital, Prague; University Hospital Hradec Kralove
Recruiting
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Posted: September 18th, 2023, 2:00pm GMT

Conditions: Neuroendocrine Carcinomas; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Carcinoma, Adrenocortical; Carcinoma, Adrenal Cortical
Interventions: Drug: ADCT-701
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Posted: August 23rd, 2023, 2:00pm GMT

Conditions: Locally Advanced Adrenal Cortex Carcinoma; Adrenal Cortical Carcinoma; Stage III Adrenal Cortex Carcinoma; Stage IV Adrenal Cortex Carcinoma AJCC v8; Unresectable Adrenal Cortex Carcinoma
Interventions: Biological: Atezolizumab; Procedure: Biospecimen Collection; Drug: Cabozantinib S-malate; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging
Sponsors: Emory University; National Cancer Institute (NCI)
Not yet recruiting
Phase 1 Study of 68Ga-R8760

Posted: August 21st, 2023, 2:00pm GMT

Conditions: Adrenocortical Carcinoma
Interventions: Drug: 68Ga-R8760 injection at pre-defined dose levels; Drug: 68Ga-R8760 injection
Sponsors: Radionetics Oncology
Recruiting
Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

Posted: June 22nd, 2023, 2:00pm GMT

Condition: Adrenocortical Carcinoma
Interventions: Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG; Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Recruiting
18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma

Posted: May 23rd, 2023, 2:00pm GMT

Conditions: Hepatocellular Carcinoma
Interventions: Diagnostic Test: 18F-FDGal PET/CT or PET/MRI
Sponsors: University of Aarhus
Recruiting
The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma

Posted: May 2nd, 2023, 2:00pm GMT

Condition: Adrenocortical Carcinoma
Intervention:
Sponsor: Shanghai Jiao Tong University School of Medicine
Not yet recruiting
European Multicenter Study on Role of Lymph Node Dissection in Surgical Management of Adrenal Cortical Carcinoma

Posted: March 10th, 2023, 3:00pm GMT

Condition: Adrenocortical Carcinoma
Intervention: Procedure: Adrenalectomy with or without lymphadenectomy
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
Positioning of Molecular Markers in Clinical Routine for the Management of Patients With Adrenal Cancers/Tumors (COMETE-CARE)

Posted: March 6th, 2023, 3:00pm GMT

Conditions: Cancer; Adrenal
Interventions: Other: Blood sample; Other: Urine sample; Other: Tumor sample
Sponsors: Assistance Publique - Hôpitaux de Paris; National Cancer Institute, France
Not yet recruiting
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Posted: December 2nd, 2022, 3:00pm GMT

Conditions: Adrenocortical Carcinoma
Interventions: Drug: Mitotane; Drug: Pembrolizumab
Sponsors: M.D. Anderson Cancer Center
Recruiting
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

Posted: October 3rd, 2022, 2:00pm GMT

Condition: Adrenocortical Carcinoma
Intervention: Drug: Pembrolizumab 25 MG/ML [Keytruda]
Sponsors: Maria Sklodowska-Curie National Research Institute of Oncology; Biostat Sp. z o.o.
Recruiting
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

Posted: February 14th, 2022, 3:00pm GMT

Conditions: Neuroendocrine Tumors; Carcinoma, Neuroendocrine
Sponsors: National Cancer Institute (NCI)
Recruiting
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Posted: September 5th, 2021, 2:00am GMT

Conditions: Adrenocortical Carcinoma
Interventions: Drug: Pembrolizumab / Lenvatinib
Sponsors: National Cancer Center, Korea; MSD Korea Ltd.
Enrolling by invitation
Milademetan in Advanced/Metastatic Solid Tumors

Posted: August 19th, 2021, 2:00pm GMT

Conditions: Solid Tumors; Head and Neck Carcinoma; Cholangiocarcinoma; Sarcoma; Lung Adenocarcinoma; Bladder Urothelial Carcinoma; Stomach Adenocarcinoma; Breast Cancer Invasive; Ovarian Carcinoma; Cervical Cancer; Non Small Cell Lung Cancer; Gastric Cancer; Biliary Tract Cancer; Melanoma; Pancreas Cancer; MDM2 Gene Amplification; Testicular Germ Cell Tumor; Adrenocortical Carcinoma
Interventions: Drug: RAIN-32
Sponsors: Rain Oncology Inc
Terminated
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction

Posted: June 25th, 2021, 2:00pm GMT

Condition: Metastatic Carcinoma
Intervention: Radiation: Stereotactic ablative body radiation therapy
Sponsors: Baptist Health South Florida; Viewray Inc.
Recruiting
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Posted: May 21st, 2021, 2:00pm GMT

Conditions: Pediatric Solid Tumor; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Ewing Sarcoma; Wilms Tumor; Adrenocortical Cancer; Desmoplastic Small Round Cell Tumor; Germ Cell Cancer; Rhabdoid Tumor; Clear Cell Sarcoma; Hepatoblastoma; Melanoma; Carcinoma; Malignant Peripheral Nerve Sheath Tumors; Soft Tissue Sarcoma
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: MESNA; Drug: B7-H3 CAR T cells
Sponsor: St. Jude Children's Research Hospital
Recruiting
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Posted: March 5th, 2021, 3:00am GMT

Conditions: Advanced Lung Carcinoma; Advanced Malignant Solid Neoplasm; Malignant Adrenal Gland Neoplasm; Metastatic Liver Carcinoma; Metastatic Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Stage III Liver Cancer; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Liver Cancer; Stage IV Lung Cancer AJCC v8; Stage IVA Liver Cancer; Stage IVA Lung Cancer AJCC v8; Stage IVB Liver Cancer; Stage IVB Lung Cancer AJCC v8
Interventions: Biological: Anti-CTLA4 Monoclonal Antibody BMS-986218; Biological: Nivolumab; Radiation: Stereotactic Body Radiation Therapy
Sponsors: M.D. Anderson Cancer Center
Active, not recruiting
Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions.

Posted: October 20th, 2020, 2:00am GMT

Conditions: Neoplasms, Colorectal
Interventions: Procedure: Endoscopic mucosal resection (EMR); Procedure: Endoscopic submucosal dissection (ESD)
Sponsors: José Carlos Marín Gabriel; Spanish Society of Digestive Endoscopy
Recruiting
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Posted: July 7th, 2020, 2:00am GMT

Conditions: Bladder Carcinoma; Cervical Carcinoma; Cholangiocarcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Hepatocellular Carcinoma; Malignant Adrenal Gland Neoplasm; Malignant Brain Neoplasm; Malignant Pleural Neoplasm; Malignant Skin Neoplasm; Malignant Solid Neoplasm; Malignant Testicular Neoplasm; Malignant Thymus Neoplasm; Neuroendocrine Neoplasm; Thyroid Gland Carcinoma; Urothelial Carcinoma; Cancer of Unknown Primary Site
Interventions: Procedure: Computed Tomography; Drug: Gallium Ga 68 FAPi-46; Procedure: Positron Emission Tomography; Radiation: 18F-FDG
Sponsors: Jonsson Comprehensive Cancer Center
Recruiting
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)

Posted: April 22nd, 2020, 2:00am GMT

Conditions: Adrenocortical Carcinoma
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Posted: February 26th, 2020, 3:00am GMT

Conditions: Malignant Solid Neoplasm; Recurrent Adrenal Gland Pheochromocytoma; Recurrent Ectomesenchymoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdoid Tumor of the Kidney; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Carcinoma; Recurrent WHO Grade 2 Glioma; Refractory Adrenal Gland Pheochromocytoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Melanoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdoid Tumor of the Kidney; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Carcinoma; Refractory WHO Grade 2 Glioma
Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration and Biopsy; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Procedure: Radionuclide Imaging; Drug: Tipifarnib
Sponsors: National Cancer Institute (NCI)
Recruiting
Stereotactic Magnetic Resonance Guided Radiation Therapy

Posted: October 3rd, 2019, 2:00am GMT

Conditions: Pancreas Cancer; Lung Cancer; Renal Cancer; Adrenal Metastases; Prostate Cancer; Liver Metastases; Oligoprogressive Nodal Metastases; Metachronous Nodal Metastases; Synchronous Nodal Metastases; Mesothelioma; Spine Metastases; Brain Metastases; Borderline Resectable Pancreatic Carcinoma
Interventions: Radiation: MR-guided Linac
Sponsors: Dana-Farber Cancer Institute
Suspended
The Registry of Oncology Outcomes Associated With Testing and Treatment

Posted: July 22nd, 2019, 2:00am GMT

Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
Sponsors: Taproot Health
Recruiting
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Posted: February 7th, 2019, 3:00pm GMT

Conditions: Solid Neoplasms; Colorectal Neoplasms; Gastrointestinal Tumors
Interventions: Drug: E7386
Sponsors: Eisai Co., Ltd.
Recruiting
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Posted: November 19th, 2018, 3:00pm GMT

Conditions: Advanced Solid Tumours; Endometrial Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Adrenocortical Carcinoma; Uveal Melanoma
Interventions: Drug: [111In]-FPI-1547 Injection; Drug: [225Ac]-FPI-1434 Injection multi-dose; Biological: FPI-1175 Infusion; Drug: [225Ac]-FPI-1434 Injection single-dose
Sponsors: Fusion Pharmaceuticals Inc.
Recruiting
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Posted: July 27th, 2018, 2:00am GMT

Conditions: Cushing Syndrome
Interventions: Drug: relacorilant
Sponsors: Corcept Therapeutics
Enrolling by invitation
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Posted: July 11th, 2018, 2:00pm GMT

Conditions: ENSAT Stage I Adrenal Cortex Carcinoma; ENSAT Stage II Adrenal Cortex Carcinoma; ENSAT Stage III Adrenal Cortex Carcinoma
Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Mitotane; Other: Quality-of-Life Assessment
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Posted: December 12th, 2017, 3:00am GMT

Conditions: Metastatic Carcinoma in the Adrenal Cortex; Stage III Adrenal Cortex Carcinoma AJCC v8; Stage IV Adrenal Cortex Carcinoma AJCC v8; Unresectable Adrenal Cortex Carcinoma
Interventions: Drug: Cabozantinib; Other: Pharmacogenomic Study; Other: Pharmacokinetic Study
Sponsors: M.D. Anderson Cancer Center
Active, not recruiting
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Posted: August 17th, 2017, 2:00am GMT

Conditions: Solid Tumors; Peritoneal Carcinomatosis
Interventions: Drug: IMP321; Drug: Avelumab
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Recruiting
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma

Posted: April 25th, 2017, 2:00pm GMT

Conditions: Adrenocortical Carcinoma; Peritoneal Carcinomatosis
Interventions: Drug: Cisplatin; Drug: Sodium thiosulfate; Procedure: Cytoreductive surgery
Sponsors: Columbia University
Recruiting
Familial Investigations of Childhood Cancer Predisposition

Posted: February 10th, 2017, 3:00pm GMT

Conditions: Acute Leukemia; Adenomatous Polyposis; Adrenocortical Carcinoma; AML; BAP1 Tumor Predisposition Syndrome; Carney Complex; Choroid Plexus Carcinoma; Constitutional Mismatch Repair Deficiency Syndrome; Diamond-Blackfan Anemia; DICER1 Syndrome; Dyskeratosis Congenita; Emberger Syndrome; Familial Acute Myeloid Leukemia; Familial Adenomatous Polyposis; Fanconi Anemia; Familial Cancer; Familial Wilms Tumor; Familial Neuroblastoma; GIST; Hereditary Breast and Ovarian Cancer; Hereditary Paraganglioma-Pheochromocytoma Syndrome; Hodgkin Lymphoma; Juvenile Polyposis; Li-Fraumeni Syndrome; Lynch Syndrome; MDS; Melanoma Syndrome; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2; Neuroblastoma; Neurofibromatosis Type 1; Neurofibromatosis Type II; Nevoid Basal Cell Carcinoma Syndrome; Non Hodgkin Lymphoma; Noonan Syndrome and Other Rasopathy; Overgrowth Syndromes; Pancreatic Cancer; Peutz-Jeghers Syndrome; Pheochromocytoma/Paraganglioma; PTEN Hamartoma Tumor Syndrome; Retinoblastoma; Rhabdoid Tumor Predisposition Syndrome; Rhabdomyosarcoma; Rothmund-Thomson Syndrome; Tuberous Sclerosis; Von Hippel-Lindau Disease
Intervention:
Sponsor: St. Jude Children's Research Hospital
Recruiting
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Posted: March 29th, 2016, 2:00am GMT

Conditions: Advanced Malignant Solid Neoplasm; Carcinoma of Unknown Primary; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Germ Cell Tumor; Metastatic Malignant Solid Neoplasm; Metastatic Paraganglioma; Metastatic Penile Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Small Cell Carcinoma; Stage III Adrenal Cortex Carcinoma AJCC v7; Stage IV Adrenal Cortex Carcinoma AJCC v7; Stage IV Penile Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma; Unresectable Skin Squamous Cell Carcinoma; Unresectable Solid Neoplasm; Vascular Neoplasm
Interventions: Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Active, not recruiting
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Posted: October 30th, 2015, 2:00am GMT

Conditions: Differentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma
Interventions: Procedure: Computed Tomography; Procedure: Dual X-ray Absorptiometry; Procedure: Physical Examination; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Cabozantinib; Drug: Lenvatinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Active, not recruiting
$Permalink for 'Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)'$
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Posted: June 8th, 2015, 2:00am GMT

Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Pancreatic Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Cancer; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Capivasertib; Procedure: Computed Tomography; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Procedure: Echocardiography; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Procedure: Radiologic Examination; Biological: Relatlimab; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

Posted: September 4th, 2013, 2:00am GMT

Conditions: Complete Remission in Renal Cell Carcinoma
Interventions: Drug: sunitinib; Drug: sunitinib
Sponsors: Pfizer
Completed
European Low and Intermediate Risk Neuroblastoma Protocol

Posted: November 16th, 2012, 3:00am GMT

Conditions: LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
Interventions: Drug: chemotherapy
Sponsors: Instituto de Investigacion Sanitaria La Fe
Completed
Natural History Study of Children and Adults With Medullary Thyroid Cancer

Posted: August 9th, 2012, 2:00am GMT

Conditions: Medullary Thyroid Cancer
Sponsors: National Cancer Institute (NCI)
Recruiting
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Posted: July 11th, 2007, 2:00am GMT

Conditions: Breast Cancer
Interventions: Biological: therapeutic autologous dendritic cells; Drug: aromatase inhibition therapy; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Drug: tamoxifen citrate; Genetic: gene expression analysis; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: biopsy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Completed
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Posted: March 17th, 2006, 3:00am GMT

Conditions: Stage I Adrenal Cortical Carcinoma AJCC v7; Stage II Adrenal Cortical Carcinoma AJCC v7; Stage III Adrenal Cortical Carcinoma AJCC v7; Stage IV Adrenal Cortical Carcinoma AJCC v7
Interventions: Drug: Cisplatin; Procedure: Conventional Surgery; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Biological: Filgrastim; Drug: Mitotane; Biological: Pegfilgrastim
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Completed

← Trial - Adrenal Cancer Google - Ampullary Cancer →

Rare Cancer News & Clinical Trials » Trial - Adrenocortical Carcinoma

Feeds

Trial - Adrenocortical Carcinoma (43 unread)

Posted: November 21st, 2023, 3:00am GMT

Posted: November 9th, 2023, 3:00am GMT

Posted: October 5th, 2023, 2:00am GMT

Posted: October 4th, 2023, 2:00am GMT

Posted: September 22nd, 2023, 2:00pm GMT

Posted: September 18th, 2023, 2:00pm GMT

Posted: August 23rd, 2023, 2:00pm GMT

Posted: August 21st, 2023, 2:00pm GMT

Posted: June 22nd, 2023, 2:00pm GMT

Posted: May 23rd, 2023, 2:00pm GMT

Posted: May 2nd, 2023, 2:00pm GMT

Posted: March 10th, 2023, 3:00pm GMT

Posted: March 6th, 2023, 3:00pm GMT

Posted: December 2nd, 2022, 3:00pm GMT

Posted: October 3rd, 2022, 2:00pm GMT

Posted: February 14th, 2022, 3:00pm GMT

Posted: September 5th, 2021, 2:00am GMT

Posted: August 19th, 2021, 2:00pm GMT

Posted: June 25th, 2021, 2:00pm GMT

Posted: May 21st, 2021, 2:00pm GMT

Posted: March 5th, 2021, 3:00am GMT

Posted: October 20th, 2020, 2:00am GMT

Posted: July 7th, 2020, 2:00am GMT

Posted: April 22nd, 2020, 2:00am GMT

Posted: February 26th, 2020, 3:00am GMT

Posted: October 3rd, 2019, 2:00am GMT

Posted: July 22nd, 2019, 2:00am GMT

Posted: February 7th, 2019, 3:00pm GMT

Posted: November 19th, 2018, 3:00pm GMT

Posted: July 27th, 2018, 2:00am GMT

Posted: July 11th, 2018, 2:00pm GMT

Posted: December 12th, 2017, 3:00am GMT

Posted: August 17th, 2017, 2:00am GMT

Posted: April 25th, 2017, 2:00pm GMT

Posted: February 10th, 2017, 3:00pm GMT

Posted: March 29th, 2016, 2:00am GMT

Posted: October 30th, 2015, 2:00am GMT

Posted: June 8th, 2015, 2:00am GMT

Posted: September 4th, 2013, 2:00am GMT

Posted: November 16th, 2012, 3:00am GMT

Posted: August 9th, 2012, 2:00am GMT

Posted: July 11th, 2007, 2:00am GMT

Posted: March 17th, 2006, 3:00am GMT